Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 1598.1% from a year ago
Other current liabilities stood at $5.18M at the end of Q1 FY2026, up 1598.1% from a year earlier.
Context
- Other current liabilities amounted to 49.3% of total assets at the end of Q1 FY2026, up 38.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +1598.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.55M USD
- Year-over-year change
- +1351.7%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.55M | +1351.7% |
| FY2024 | 2024-12-31 | 382.2K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1598.1% is the highest of 9, against a peer median of -42.3%.
- Other current liabilities amounts to 49.3% of total assets for GLSI, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.15M USD | -74.2% | -6.4% | 15.1% | |
| Mar 2026 | $5.18M USD | +1598.1% | — | 49.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.12M USD | -67.6% | — | 6.2% |
| Mar 2026 | $3M USD | +101.8% | -3.9% | 1.1% | |
| Mar 2026 | $880.67K USD | +20.3% | — | 0.9% | |
| Mar 2026 | $498K USD | -17.0% | +21.7% | 1.4% | |
| Mar 2026 | $340K USD | +34.4% | -20.8% | 0.3% | |
| Mar 2026 | $197.59K USD | -86.4% | +31.2% | 0.7% | |
| Mar 2026 | CA$0 CAD | -100.0% | +246.9% | 0.0% | |
| Peer median (excluding GLSI) | — | -42.3% | +8.9% | 1.0% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.